Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858626 | 1.00 | ATM (0.56) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL8530402 | 0.86 | ATM (0.68) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL30460502 | 0.86 | ATM (0.68) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL21469067 | 0.86 | ATM (0.68) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL12951666 | 0.85 | ATM (0.60) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL21399863 | 0.85 | ATM (0.60) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL21404926 | 0.85 | ATM (0.60) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL8241135 | 0.85 | ATM (0.56) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL8240521 | 0.85 | ATM (0.56) | ATMALDH1A1CYP3A4TSHRCTSL | |
| SCHEMBL27733208 | 0.85 | ATM (0.56) | ATMALDH1A1CYP3A4TSHRCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831080-B2 | E.g., 3-(2-fluorophenyl)-N-(1-(3-morpholin-4-yl)phenyl)-propyl)acrylamide; disorders responsive to opening of KCNQ potassium channels; analgesics; migraine, bipolar disorders, anticonvulsants, antiepileptic, anxiolytic agents | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-14 | — | — | US | disclosed |
| EP-1392644-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| WO-2002096858-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | ATM 4336/4885ALDH1A1 2914/4885CYP3A4 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.